title: Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML.
abstract: We monitored DLI treatment of 13 post-SCT relapses using quantitative competitive (QC) RT-PCR for BCR-ABL (sensitivity 10(-5)) and compared responses to DLI alone and DLI in combination with interferon-alpha (IFN). Ten relapses (one blast crisis, five cytogenetic and four molecular) were treated with DLI+IFN, three relapses (one cytogenetic, two molecular) were treated with DLI alone. Except the patient treated in blast crisis, who died, all the patients treated with DLI+IFN achieved complete molecular remission, with the median time interval of 3.9 months (range 0.25-10.5 months). None of the three patients treated with DLI alone have achieved complete molecular remission up to now, i.e. 32, 45, and 50 months after DLI. However, in all of them some decrease of BCR-ABL transcript level was detected. Although the retrospective analyses did not confirm that IFN improved the response to DLI, our results based on sensitive molecular monitoring suggest that DLI effect, at least in some patients, is supported by IFN administration.
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic. jana.moravcova@uhkt.cz
authors.forename: Jana
authors.initials: J
authors.lastname: Moravcová
authors.forename: Sylvie
authors.initials: S
authors.lastname: Nádvorníková
authors.forename: Václava
authors.initials: V
authors.lastname: Zmeková
authors.forename: Kyra
authors.initials: K
authors.lastname: Michalová
authors.forename: Jana
authors.initials: J
authors.lastname: Brezinová
authors.forename: Marcela
authors.initials: M
authors.lastname: Lukásová
authors.forename: Antonín
authors.initials: A
authors.lastname: Vítek
authors.forename: Jan
authors.initials: J
authors.lastname: Hrabánek
authors.forename: Zdenka
authors.initials: Z
authors.lastname: Gasová
authors.forename: Petr
authors.initials: P
authors.lastname: Sedlácek
authors.forename: Jan
authors.initials: J
authors.lastname: Starý
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques; D012333:RNA, Messenger / Q000032:analysis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D016898:Interferon-alpha; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl